CS
TLSI icon

Clear Street’s TriSalus Life Sciences TLSI Stock Holding History

Clear Street’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$6 – 756
2024
Q2 		$6 Hold
1
– – ﹤0.01% 784
2024
Q1 		$10 Buy
+1
New +$9 ﹤0.01% 778
2023
Q2 		– Sell
-65
Closed -$663 – 1367
2023
Q1 		$663 Buy
+65
New +$659 ﹤0.01% 1004

Other funds holding TLSI

WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.39B AUM 17.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Clear Street's TLSI Position: Q3 2024 in Review

Clear Street sold out of TriSalus Life Sciences (TLSI) in Q3 2024, closing a stake of 1 share — an estimated $6 sold.

Clear Street first reported a position in TLSI in Q1 2023 and held it in 3 quarters. The position peaked at $663 in Q1 2023. 32 funds tracked by Wall St. Rank hold TLSI as of Q3 2024.

  • Clear Street reported no remaining TriSalus Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Clear Street sold 1 TriSalus Life Sciences share in Q3 2024, an estimated $6.
  • Clear Street first reported a position in TriSalus Life Sciences in Q1 2023 and held it in 3 quarters.
  • Clear Street's TriSalus Life Sciences position peaked at $663 in Q1 2023.
  • 32 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2024.

Based on Clear Street's 13F filing for Q3 2024, filed 14 Nov 2024.